WO 2004/087721 PCT/US2004/009088

The embodiments of the invention in which an exclusive property or privilege is claimed are defined as follows:

- 1. A sodium ion absorption and/or inducible nitric oxide synthase (iNOS) inhibiting camphanylidene or phenyl alkyl inositol polyphosphate compound, or a stereoisomer, racemate, prodrug or a pharmaceutically acceptable salt thereof.
- 2. A camphanylidene inositol polyphosphate compound selected from the group consisting of 2,3-camphanylidene-*myo*-inositol 1,4,5,6-tetrakisphosphate, 1,2-camphanylidene-*myo*-inositol 3,4,5,6-tetrakisphosphate, and the stereoisomers, racemates, prodrugs, esters and pharmaceutically acceptable salts thereof.
- 3. A compound of Claim 2, which is an ester selected from the group consisting of acetoxymethylesters (AM-esters), propionoxymethylesters (PM-esters) or pivaloyloxymethyl esters.
- 4. A compound of Claim 3 selected from the group consisting of 2,3-camphanylidene-*myo*-inositol 1,4,5,6-tetrakisphosphate octakis (propionoxymethyl) ester, and 1,2-camphanylidene-*myo*-inositol 3,4,5,6-tetrakisphosphate octakis (propionoxymethyl) ester, and the stereoisomers, racemates, prodrugs, and pharmaceutically acceptable salts thereof.
- 5. A method for inhibiting sodium ion absorption by epithelial cells, comprising treating the cells with an effective amount of a sodium uptake inhibiting camphanylidene and/or phenyl alkyl inositol polyphosphate compound.
- 6. A method for inhibiting sodium ion absorption by epithelial cells in a human or animal patient in need of such treatment, comprising administering to the patient a therapeutically effective amount of a sodium uptake inhibiting camphanylidene and/or phenyl alkyl inositol polyphosphate compound.

WO 2004/087721 PCT/US2004/009088

7. A method of Claim 6, wherein the sodium uptake inhibiting camphanylidene and/or phenyl alkyl inositol polyphosphate compound is a sodium uptake inhibiting inositol polyphosphate compound.

- 8. A method of Claim 6, wherein the camphanylidene inositol polyphosphate compound is selected from the group consisting of 2,3-camphanylidene-*myo*-inositol 1,4,5,6-tetrakisphosphate, 1,2-camphanylidene-*myo*-inositol 3,4,5,6-tetrakisphosphate, and the stereoisomers, racemates, prodrugs, esters and a pharmaceutically acceptable salts thereof.
- 9. A method of Claim 8, which is an ester selected from the group consisting of acetoxymethylesters (AM-esters), propionoxymethylesters (PM-esters) or pivaloyloxymethyl esters.
- 10. A method of Claim 9 selected from the group consisting of 2,3-camphanylidene-*myo*-inositol 1,4,5,6-tetrakisphosphate octakis (propionoxymethyl) ester, and 1,2-camphanylidene-*myo*-inositol 3,4,5,6-tetrakisphosphate octakis (propionoxymethyl) ester, and the stereoisomers, racemates, prodrugs, and pharmaceutically acceptable salts thereof.